MedTrace Logo

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

NCT04648241 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2023-11-22

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.

Conditions

  • Tick-Borne Encephalitis

Interventions

BIOLOGICAL

TBE vaccine 0.5 mL

TBE vaccine 0.5 mL (intramuscular injection).

BIOLOGICAL

TBE vaccine 0.25 mL

TBE vaccine 0.25 mL (intramuscular injection).

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2022-02-21
Completion
2022-02-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648241 on ClinicalTrials.gov